Jeudi, 29 Octobre 2020
Dernières nouvelles
Principale » Glaukos Corporation (NYSE:GKOS) CFO Purchases $50064.00 in Stock

Glaukos Corporation (NYSE:GKOS) CFO Purchases $50064.00 in Stock

14 Décembre 2017

Glaukos Corp (NYSE:GKOS) shares traded -4.28% down during most recent session to reach at the closing price of $24.85. Wall Street analysts have a consensus 1.50 recommendation on the stock. Wells Fargo & Company MN owned 3.70% of Glaukos worth $42,003,000 at the end of the most recent quarter.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Shaker Investments LLC OH raised its position in Glaukos by 6.3% in the third quarter. Arrowstreet Capital Limited Partnership now owns 15,300 shares of the medical instruments supplier's stock worth $634,000 after acquiring an additional 6,676 shares during the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of Glaukos by 740.6% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier's stock worth $147,000 after buying an additional 3,118 shares during the period. Quantbot Technologies LP increased its holdings in Glaukos by 291.3% in the 3rd quarter. Finally, UBS Asset Management Americas Inc. acquired a new position in shares of Glaukos in the 2nd quarter valued at $274,000. Zacks Investment Research's sales calculations are a mean average based on a survey of research analysts that cover Glaukos.

WARNING: "Glaukos Corporation (GKOS) Expected to Announce Quarterly Sales of $40.81 Million" was first published by StockNewsTimes and is the property of of StockNewsTimes. Stephens reiterated an "overweight" rating and issued a $40.00 price target (down previously from $47.00) on shares of Glaukos in a research report on Monday, November 13th. BidaskClub upgraded Glaukos from a "sell" rating to a "hold" rating in a research report on Friday, September 1st. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Uptrending stocks trade above their moving averages, while downtrending stocks trade below.

In order to gauge which way a stock is trending, you must compare a stock's share price to its moving average. The stock has a market cap of $897.32, a P/E ratio of 216.33 and a beta of 1.02.

Morgan Spurlock Admits Past Sexual Misconduct 'I am Part of the Problem'
In a tweet after his blog post, Spurlock said he was "seeking help". We took off our clothes. 'I didn't know what to do, ' he writes. I tried to comfort her. "She believed she was raped".

This stock (GKOS) is ahead of its 52-week low with 6.02%. The consensus mean EPS for the current quarter is at $0.01 derived from a total of 8 estimates from the analysts who have weighed in on projected earnings. The firm had revenue of $40.41 million for the quarter, compared to analyst estimates of $38.69 million. Glaukos had a positive return on equity of 3.50% and a negative net margin of 0.64%. During the same period in the previous year, the company posted $0.03 earnings per share. equities analysts forecast that Glaukos Corporation will post -0.03 earnings per share for the current fiscal year.

In other Glaukos news, CEO Thomas William Burns sold 73,788 shares of the stock in a transaction dated Thursday, September 7th. The shares were purchased at an average cost of $23.84 per share, for a total transaction of $50,064.00. Following the acquisition, the chief financial officer now directly owns 102,100 shares of the company's stock, valued at $2,434,064. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Glaukos Corporation (NYSE:GKOS) closed its last session at $24.85. The correct version of this report can be accessed at https://www.truebluetribune.com/2017/12/12/wells-fargo-company-mn-decreases-position-in-glaukos-corporation-gkos.html.

Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma.